Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Hans-Christian PommergaardC W YdeL B AhlbornC L AndersenT V HenriksenJ P HasselbyA A RostvedC L SørensenK S RohrbergF C NielsenA RasmussenPublished in: Molecular biology reports (2021)
In patients with resectable HCC, ctDNA could not be reliably detected using the applied targeted NGS method. In contrast, ctDNA was detected in all patients with advanced HCC. Small tumors, tumor heterogeneity and limited sequencing coverage may explain the lack of detectable ctDNA.